טוען...
Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors
Predictive biomarkers of response to immune checkpoint inhibitors (ICI) help to identify cancer patients who will benefit from immunotherapy. Protein kinase, DNA‐activated, catalytic subunit (PRKDC) is an important gene for DNA double‐strand break (DSB) repair and central T‐cell tolerance. We aimed...
שמור ב:
| הוצא לאור ב: | Mol Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7463346/ https://ncbi.nlm.nih.gov/pubmed/32502294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12739 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|